REG - Hemogenyx Pharma Plc - Total Voting Rights

Hemogenyx PharmaceuticalsAnnouncement

29/05/2020 07:01

RNS Number : 1075O
  
Hemogenyx Pharmaceuticals PLC
  
29 May 2020
  
 

 
29 May 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Total Voting Rights 
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company consists of 397,921,969 ordinary shares of 1 penny each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 397,921,969. 
The figure of 397,921,969 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:



Hemogenyx Pharmaceuticals plc


https://hemogenyx.com




Dr Vladislav Sandler, Chief Executive Officer & Co-Founder


headquarters@hemogenyx.com




Peter Redmond, Director


















SP Angel Corporate Finance LLP


Tel: +44 (0)20 3470 0470




Matthew Johnson, Vadim Alexandre, Soltan Tagiev


















Peterhouse Capital Limited


Tel: +44 (0)20 7469 0930




Lucy Williams, Duncan Vasey, Charles Goodfellow


















US Media enquiries


Tel: +1 (323) 646-3249




Lowell Goodman


lowell@corbomitecomms.com



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
TVREAFSXASNEEFA